| abstract |
The invention provides novel beta-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic beta-lactamase inhibitors presently available, and which do not possess beta-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as beta-lactamase inhibitors and as antibiotics. |